Icahn School of Medicine at Mount Sinai Listed a New Clinical Trial to Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma (CC-220)

Press/Media

Period	29 Sep 2022

Media coverage

Title	Icahn School of Medicine at Mount Sinai Listed a New Clinical Trial to Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma (CC-220)
Media name/outlet	India Pharma News
Country/Territory	India
Date	29/09/22
URL	ct.moreover.com/?a=48884848875&p=1gw&v=1&x=4wjNG_bb_24qzozoIxtmqg
Persons	Samir Parekh